This is a limited-confidence, manager-run pre-tax scenario range for one standard U.S. Medicap Pharmacy retail location—not a franchisor-reported result. The base scenario is approximately $205,000. A licensed pharmacist owner who genuinely replaces a fully paid pharmacist role could have a conditional owner-operator benefit of roughly $166,000–$572,000, but the added amount compensates the owner for labor and is not passive business profit.
The range is an independent analytical scenario. It is not an Item 19 financial performance representation by Medicap Pharmacies Incorporated. It combines identified facts from the 2025 Medicap Pharmacy Franchise Disclosure Document with National Community Pharmacists Association, Internal Revenue Service, and Bureau of Labor Statistics benchmarks, plus explicitly labeled scenario spreads. Actual results can differ materially because of prescription reimbursement, product mix, acquisition cost, location, store format, labor, occupancy, financing, owner involvement, and execution.
Estimated pre-tax residual before personal taxes and financing principal.
NCPA average annual sales per independent community pharmacy location in 2024.
IRS 2022 Health and Personal Care Retailers net income divided by total receipts.
BLS May 2024 median annual wage in pharmacies and drug retailers.
System count at June 30, 2025; the outlet table includes retail pharmacies and five telepharmacies.
$599 monthly under the qualifying purchasing election, or 3% of Gross Sales otherwise.
What does the 2025 Medicap Pharmacy FDD actually disclose?
Officially, the FDD discloses no sales, operating profit, EBITDA, net income, cash flow, owner compensation, or owner earnings for Medicap Pharmacy outlets. The earnings section states that Medicap does not make a financial performance representation and does not provide past financial performance for company-owned or franchised outlets. That makes the evidence mode a structural FDD-anchored estimate rather than an official or FDD-derived earnings result. Source: 2025 Medicap Pharmacy FDD, Item 19, p. 40.
The distinction is decisive: Gross Sales cannot be renamed owner income, and an external industry average cannot be presented as a Medicap result. The Federal Trade Commission’s Item 19 guidance explains that a franchisor is not required to provide an earnings claim, but financial performance claims made in the sales process generally belong in Item 19 and require substantiation.
The strongest current external sales benchmark is $5.411 million per location, while the corresponding independent-pharmacy gross profit margin was 18.2%. That implies about $985,000 of gross profit before payroll, occupancy, professional staffing, insurance, technology, franchise obligations, interest, depreciation, and other operating deductions. Gross profit is therefore not owner earnings.
Which outlets and formats can be compared without guessing?
The scenario applies only to a standard U.S. retail pharmacy location. The FDD describes new stores and conversions and uses an approximately 2,500-square-foot store as its standard physical reference. The official Medicap Pharmacy franchise website also describes new-pharmacy, acquisition, and co-brand paths. The outlet table, however, combines retail pharmacies with five telepharmacies in its system count, and no company-operated Medicap Pharmacy outlets existed during the reported period. Those populations should not be blended into one earnings claim. Sources: 2025 Medicap Pharmacy FDD, Items 1, 7, and 20, pp. 1–4, 17–20, and 41–46.
How was the annual owner-earnings range estimated?
The estimate multiplies an independent-pharmacy revenue anchor by a broad official net-income margin proxy. It is an independent Mode D calculation for one operating standard retail location, not a forecast for a new opening, conversion ramp, telepharmacy, or specific market.
- Revenue anchor: $5.411 million, the NCPA-reported average annual sales per independent community pharmacy location for 2024. Because the FDD supplies no Medicap sales distribution, the conservative and upside revenue anchors are explicit analytical assumptions at 80% and 120% of that figure: $4.329 million and $6.493 million.
- Margin anchor: IRS Statistics of Income 2022 Publication 16, Table 5.1 reports $23.102 billion of net income less deficit and $610.787 billion of total receipts for Health and Personal Care Retailers. The compatible ratio is 3.78%. This is broader than the exact NAICS 456110 Pharmacies and Drug Retailers definition, so confidence is limited.
- Margin sensitivity: With no same-brand margin distribution, the conservative and upside margins are explicit assumptions at 3 percentage points below and above the 3.78% proxy: 0.78% and 6.78%. These are sensitivity cases, not probabilities, quartiles, or franchisor expectations.
- Definition: The output is estimated pre-tax business earnings based on a broad corporate net-income margin, before personal income taxes and financing principal. Interest, depreciation, wages, and officer compensation are embedded in the IRS aggregate; capital expenditures and working-capital changes are not. The source does not separate owner compensation, manager compensation, or Medicap-specific recurring fees.
- Excluded precision: Capital expenditures, working-capital changes, inventory financing, acquisition debt, personal taxes, and location-specific reimbursement contracts are not modeled. Item 10 states that Medicap offers no direct or indirect financing.
Annual pre-tax residual for one standard retail pharmacy, rounded to the nearest $1,000.
Interpretation: Most of the range comes from uncertainty in both revenue and the net-income margin. The $205,000 base is a midpoint scenario, not the “most likely” result.
Sources and calculation: NCPA 2025 Digest data for 2024 average sales, reported in America’s Pharmacist, November 2025, p. 15; IRS SOI 2022 Publication 16, Table 5.1. Formula using unrounded inputs: $4,328,800 × 0.7823728% = $33,867; $5,411,000 × 3.7823728% = $204,664; $6,493,200 × 6.7823728% = $440,393. Displayed values are rounded to the nearest $1,000.
These endpoints are intentionally wide because the low case combines lower sales with a lower margin, while the high case combines higher sales with a higher margin. They are not confidence intervals or probabilities. A location can land between the endpoints in one variable and outside them in another. High sales with weak reimbursement can produce less cash than the base case, while lower sales with favorable mix and tighter labor control can outperform it. A buyer should rerun the model with the candidate store’s monthly statements rather than treating the midpoint as the expected outcome.
The central revenue figure is a current independent-community-pharmacy average, but it is not Medicap-specific. The margin is a 2022 IRS corporate proxy for the broader Health and Personal Care Retailers category, not a same-brand or exact pharmacy-only operating margin. Those two compatibility gaps are the main reason the range is wide.
How does owner involvement change the result?
Owner involvement can add labor value, but it does not automatically increase pure business profit. Item 15 recommends personal participation but does not require it; the business must remain under the supervision of a properly licensed pharmacist. Therefore, a non-pharmacist owner cannot simply add a pharmacist wage to earnings, and a licensed pharmacist owner can do so only when that owner truly replaces a paid pharmacist position already embedded in a manager-run cost structure. Source: 2025 Medicap Pharmacy FDD, Item 15, p. 35.
- Manager-run pre-tax owner earnings
- Residual business economics after normal operating deductions represented by the margin proxy. It excludes personal income taxes and financing principal and does not assign a separate wage to the owner.
- Estimated owner-operator benefit
- Manager-run residual plus the market value of a paid role the owner replaces. It combines business profit and compensation for the owner’s labor, so it is not passive income.
- Pharmacist labor assumption
- $131,640, the BLS May 2024 median annual wage for pharmacists employed in pharmacies and drug retailers. Benefits, payroll taxes, overtime, relief coverage, and local wage differences are not added.
- Double-counting guardrail
- Do not add the wage when owner compensation is already recorded in payroll, officer compensation, or distributions, or when the owner does not replace a full paid position.
The owner-operator point adds $131,640 of pharmacist labor value to each scenario.
Interpretation: The $131,640 gap is compensation for professional labor, not an automatic improvement in the pharmacy’s underlying margin. The owner-operated figures are valid only under the replacement-role assumption.
Source: U.S. Bureau of Labor Statistics, Pharmacists, May 2024 median wage for pharmacies and drug retailers. BLS wage data exclude self-employed workers, which is why the figure is used as a replacement-cost benchmark rather than reported owner compensation. Calculations: $33,867 + $131,640 = $165,507; $204,664 + $131,640 = $336,304; $440,393 + $131,640 = $572,033. Displayed values are rounded.
How much can the continuing license fee move cash flow?
The direct annual invoice can differ by more than $122,000–$187,000 across the scenario sales levels, depending on which FDD fee path applies. Item 6 lists a Continuing License Fee of 3% of Gross Sales, or $599 per month when the franchisee makes the qualifying election to purchase at least 95% of pharmaceutical inventory from Cardinal Health or an affiliate, subject to the FDD’s buying-group provisions. The fixed fee annualizes to $7,188 before any permitted inflation adjustment. Sources: 2025 Medicap Pharmacy FDD, Items 5 and 6, pp. 10–16.
| Scenario sales | 3% of Gross Sales | $599 monthly path | Direct fee difference |
|---|---|---|---|
| Conservative: $4.329M | $129,864 | $7,188 | $122,676 |
| Base: $5.411M | $162,330 | $7,188 | $155,142 |
| Upside: $6.493M | $194,796 | $7,188 | $187,608 |
The table is a direct invoice comparison, not a conclusion that one path always produces higher owner earnings. The fixed-fee path is linked to pharmaceutical purchasing commitments, and drug acquisition economics can materially affect the 18.2% industry gross margin. Because the earnings model uses an all-in IRS net-income proxy, the Medicap fee is not subtracted again inside the three scenario results; doing so without knowing whether and how the proxy already reflects comparable fees would create false precision. A buyer should model wholesaler pricing, rebates, purchasing-group terms, inventory carrying cost, and the license invoice together.
Which variables can move Medicap Pharmacy owner earnings the most?
Prescription reimbursement and gross margin are the largest unresolved drivers, followed by pharmacist staffing, the purchasing-fee path, and occupancy. This is an estimated answer for a standard retail pharmacy; none of these variables is quantified for a comparable outlet cohort.
- Reimbursement and product mix
- The 2025 NCPA Digest reported a 10-year high in average sales but a 10-year low in gross profit for 2024. High-cost, narrow- or negative-margin prescriptions can increase revenue without proportionately increasing owner earnings. See the 2025 NCPA Digest release.
- Licensed-pharmacist coverage
- The FDD requires supervision by a licensed pharmacist. One additional full paid pharmacist position can consume an amount comparable to the BLS $131,640 wage benchmark before benefits and payroll burden.
- Occupancy and store format
- Item 7 reports recent franchisee rent of $2,700–$6,000 per month for an approximately 2,500-square-foot location, or $32,400–$72,000 annually before related occupancy costs. A conversion, co-brand, or telepharmacy can have a different cost structure.
- System population and survivorship
- Item 20 shows franchised outlets declining from 74 at the start of fiscal 2023 to 59 at June 30, 2025. That does not prove a particular earnings level, but it makes closure, transfer, nonrenewal, and excluded-outlet questions essential when evaluating any informal performance claim.
- Owner compensation accounting
- Salary, officer compensation, draws, distributions, and retained earnings are not interchangeable. The IRS margin is after aggregate corporate compensation deductions, but it does not show how pharmacy owners were paid.
- Debt and capital needs
- Item 10 provides no franchisor financing. The scenario excludes financing principal and does not model a buyer’s acquisition loan, working-capital line, inventory financing, remodels, or replacement equipment. Personal income taxes are also excluded.
Cardinal Health’s May 2026 discussion of pharmacy resilience and declining gross margins is consistent with treating margin as the central sensitivity rather than assuming sales growth automatically raises take-home economics.
What should a buyer verify before relying on this range?
A buyer should replace every broad benchmark with outlet-specific written evidence wherever possible. The current FDD provides no comparable sales or earnings cohort, so franchisee interviews and actual financial records carry unusual importance.
- Item 19 and written substantiation: Confirm that the final FDD still contains no earnings claim. Ask whether any later amendment changes Item 19 and request written substantiation for every sales, margin, prescription-volume, or earnings statement made during the sales process.
- Comparable franchisee P&Ls: Ask current and former owners for trailing-12-month Gross Sales, prescription revenue, gross profit, payroll, pharmacist coverage, rent, technology, insurance, interest, depreciation, owner compensation, distributions, and capital expenditures. Separate retail pharmacies from telepharmacies and mature stores from recent openings or conversions.
- Purchasing economics: Compare the 3% Continuing License Fee with the $599 monthly path using actual Cardinal Health or approved buying-group acquisition cost, rebates, payment terms, inventory turns, and any minimum-purchase obligations.
- Owner-role recast: Identify whether the seller’s reported profit already includes an owner pharmacist’s unpaid or below-market labor. Recast one P&L as manager-run and another as owner-operated without counting the same labor twice.
- Closure and transfer context: Use Item 20 and the franchisee lists to interview outlets that closed, transferred, did not renew, or left the system, not only currently operating high performers.
- Debt-service schedule: Build a separate annual principal-and-interest schedule from actual lender terms. Do not treat the $34,000–$440,000 operating range as after-debt cash or after-tax take-home pay.
What is the most defensible earnings takeaway?
The strongest defensible range is approximately $34,000–$440,000 in annual manager-run pre-tax owner earnings per standard retail location, with a $205,000 base scenario. It is scenario-based, not official, because the September 18, 2025 Medicap Pharmacy FDD contains no Item 19 financial performance representation. The most important earnings driver is pharmacy gross margin after reimbursement and acquisition cost; the largest unresolved uncertainty is the absence of same-brand outlet sales, expense, owner-compensation, and closure-cohort data.
A licensed pharmacist owner may create a conditional owner-operator benefit of about $166,000–$572,000 only when the owner replaces a full paid pharmacist role and the original P&L does not already include that labor. Before making a decision, the buyer should reconcile Item 19, written substantiation, the Continuing License Fee and purchasing arrangement, actual franchisee P&Ls, Item 20 departures, and franchisee interviews. Debt principal and personal income taxes must remain separate from the operating-earnings range.